CHA is the leading organizer and facilitator of biopharmaceutical collaboration. We reduce the costs of R&D by bringing together different companies to work cooperatively to evaluate novel technologies, assess vendors in emerging global markets and address other areas of shared concern.
We accomplish this through short, six-month collaborative projects, market research surveys, roundtable summits, virtual meetings (via tele/web conference) and the Drug Safety Executive Council (an exclusive online community of industry leaders).
“CHA does a very professional and effective job facilitating peer-to-peer collaboration. The consortium approach is a very powerful model to evaluate new technologies."
- Dr. Stefan Mueller, Senior Toxicologist, Merck Serono Research
“Groups are remarkably smart, smarter even sometimes than the smartest people in them.”
- James Surowiecki, author of Wisdom of Crowds